AtriCure vs Inspire Medical Systems
ATRC and INSP side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ATRC and INSP compare
AtriCure is the larger company, worth 1.6 times as much as Inspire Medical Systems ($3.1B against $2.0B).
On earnings, Inspire Medical Systems is cheaper: it trades at 14.7× trailing earnings, against 292× for AtriCure.
AtriCure grew revenue faster over the last twelve months (13.9% versus 4.3% for Inspire Medical Systems).
Inspire Medical Systems keeps more of each dollar of sales as profit, with a net margin of 15.0% compared with 1.9% at AtriCure.
Inspire Medical Systems scores higher on the StockData Score (17 against 12 for AtriCure), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ATRC | INSP |
|---|---|---|
| Size and price | ||
| Market cap | $3.1B | $2.0B |
| Share price | $61.25 | $68.10 |
| Change, 1 year | 72.8% | −9.4% |
| Change, 5 years | −29.7% | −75.4% |
| Beta (5Y) | 1.28 | 1.07 |
| Employees | 1,350 | 1,333 |
| StockData Score | ||
| Total score | 12 | 17 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 4 (better) | 3 |
| Performance score | 3 | 4 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 292× | 14.7× (better) |
| P/S | 5.5× | 2.2× (better) |
| P/B | 6.0× | 2.4× (better) |
| EV/EBITDA | 233× | 23.1× (better) |
| P/FCF | 58.7× | 16.8× (better) |
| FCF yield | 1.7% | 5.9% (better) |
| Fair value | $5.36 | $100.68 |
| Margin of safety | −1042% | 32.4% (better) |
| Growth | ||
| Revenue growth (TTM) | 13.9% (better) | 4.3% |
| Revenue growth, 5Y average | 20.9% | 51.2% (better) |
| Net income growth (TTM) | – | 154% |
| EPS growth (TTM) | – | 166% |
| Profitability | ||
| Gross margin | 76.3% | 86.1% (better) |
| Operating margin | 2.3% | 6.0% (better) |
| Net margin | 1.9% | 15.0% (better) |
| FCF margin | 9.3% | 13.0% (better) |
| Return on equity | 2.2% | 18.0% (better) |
| Return on invested capital | 2.7% | 12.3% (better) |
| Financial health | ||
| Debt / equity | 0.12 (better) | 0.00 |
| Net debt / EBITDA | −8.28 | – |
| Interest coverage | 2.3× | – |
| Current ratio | 4.22 | 8.55 (better) |
| Altman Z-score | 12.20 | 13.39 (better) |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Buyback yield | – | 5.1% |
| Shareholder yield | 0.00% | 5.1% (better) |
| Ownership | ||
| Held by institutions | 104% | 132% |
| Held by insiders | 4.0% | 1.6% |
| Insider net buying, 12 months | −$4.4M | −$666K (better) |
| Short interest, % of float | 9.9% | 14.8% |
Go deeper
- ATRC stock overview
- ATRC income statement
- ATRC valuation and score
- INSP stock overview
- INSP income statement
- INSP valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.